- call +1-201-465-4211
- email sales@mrinsights.biz
Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to medical or surgical treatment. Risk factor for castration resistant prostate cancer includes genetic predisposition, geriatric population, unhygienic diet, medication exposure and many sexual partners. Diagnosis for the detection of castration resistant prostate cancer includes prostate imaging, biopsy, tumor marker and staging test. Crucial factor about castration resistant prostate cancer is that it is resistant to medical and surgical treatment. However, other treatment options that are available in the market include hormone therapy, immune modulation, antiangiogenic treatment and bone targeted therapies.
Scope of the Report:
This report studies the Castration Resistant Prostate Cancer Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Castration Resistant Prostate Cancer Treatment market by product type and applications/end industries.
North America dominates the global market for castration resistant prostate cancer treatment due to presence of large prostate cancer population in this region. Moreover, increasing demand of diagnostic test, increasing awareness among people and initiative taken by the federal government also accounted for the market growth in North American region. Europe represents the second position in the global castration resistant prostate cancer treatment market due to presence of large geriatric population base in European region. Asia-Pacific is considered as an untapped market due to lack of awareness and lack of proper healthcare facilities in some Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Similarly, Asia-Pacific is considered as an emerging market during the study period due to growing market penetration in this region.
The global Castration Resistant Prostate Cancer Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Castration Resistant Prostate Cancer Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others
Market Segment by Applications, can be divided into
Hospital
Ambulatory Surgical Centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Castration Resistant Prostate Cancer Treatment Market Overview
1.1 Product Overview and Scope of Castration Resistant Prostate Cancer Treatment
1.2 Classification of Castration Resistant Prostate Cancer Treatment by Types
1.2.1 Global Castration Resistant Prostate Cancer Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Types in 2017
1.2.3 Hormonal Therapy
1.2.4 Adding An Anti-Androgen
1.2.5 Stopping An Anti-Androgen
1.2.6 Estrogens
1.2.7 Chemotherapy
1.2.8 Radiation Therapy
1.2.9 Others
1.3 Global Castration Resistant Prostate Cancer Treatment Market by Application
1.3.1 Global Castration Resistant Prostate Cancer Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital
1.3.3 Ambulatory Surgical Centers
1.4 Global Castration Resistant Prostate Cancer Treatment Market by Regions
1.4.1 Global Castration Resistant Prostate Cancer Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Castration Resistant Prostate Cancer Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Castration Resistant Prostate Cancer Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Castration Resistant Prostate Cancer Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Castration Resistant Prostate Cancer Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Castration Resistant Prostate Cancer Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Castration Resistant Prostate Cancer Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Active Biotech
2.1.1 Business Overview
2.1.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Active Biotech Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 Diagnocure
2.2.1 Business Overview
2.2.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Diagnocure Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Glaxosmithkline
2.3.1 Business Overview
2.3.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Northwest Biotherapeutics
2.4.1 Business Overview
2.4.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 Millennium Pharmaceuticals
2.5.1 Business Overview
2.5.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.6 Hologic
2.6.1 Business Overview
2.6.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Hologic Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.7 Spectrum Pharmaceuticals
2.7.1 Business Overview
2.7.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.8 Abbott Laboratories
2.8.1 Business Overview
2.8.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.9 Bayer Healthcare Pharmaceuticals
2.9.1 Business Overview
2.9.2 Castration Resistant Prostate Cancer Treatment Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Castration Resistant Prostate Cancer Treatment Market Competition, by Players
3.1 Global Castration Resistant Prostate Cancer Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Castration Resistant Prostate Cancer Treatment Players Market Share
3.2.2 Top 10 Castration Resistant Prostate Cancer Treatment Players Market Share
3.3 Market Competition Trend
4 Global Castration Resistant Prostate Cancer Treatment Market Size by Regions
4.1 Global Castration Resistant Prostate Cancer Treatment Revenue and Market Share by Regions
4.2 North America Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
5 North America Castration Resistant Prostate Cancer Treatment Revenue by Countries
5.1 North America Castration Resistant Prostate Cancer Treatment Revenue by Countries (2013-2018)
5.2 USA Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
6 Europe Castration Resistant Prostate Cancer Treatment Revenue by Countries
6.1 Europe Castration Resistant Prostate Cancer Treatment Revenue by Countries (2013-2018)
6.2 Germany Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
6.4 France Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Castration Resistant Prostate Cancer Treatment Revenue by Countries
7.1 Asia-Pacific Castration Resistant Prostate Cancer Treatment Revenue by Countries (2013-2018)
7.2 China Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
7.5 India Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
8 South America Castration Resistant Prostate Cancer Treatment Revenue by Countries
8.1 South America Castration Resistant Prostate Cancer Treatment Revenue by Countries (2013-2018)
8.2 Brazil Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Castration Resistant Prostate Cancer Treatment by Countries
9.1 Middle East and Africa Castration Resistant Prostate Cancer Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Castration Resistant Prostate Cancer Treatment Revenue and Growth Rate (2013-2018)
10 Global Castration Resistant Prostate Cancer Treatment Market Segment by Type
10.1 Global Castration Resistant Prostate Cancer Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Castration Resistant Prostate Cancer Treatment Market Forecast by Type (2018-2023)
10.3 Hormonal Therapy Revenue Growth Rate (2013-2023)
10.4 Adding An Anti-Androgen Revenue Growth Rate (2013-2023)
10.5 Stopping An Anti-Androgen Revenue Growth Rate (2013-2023)
10.6 Estrogens Revenue Growth Rate (2013-2023)
10.7 Chemotherapy Revenue Growth Rate (2013-2023)
10.8 Radiation Therapy Revenue Growth Rate (2013-2023)
10.9 Others Revenue Growth Rate (2013-2023)
11 Global Castration Resistant Prostate Cancer Treatment Market Segment by Application
11.1 Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Application (2013-2018)
11.2 Castration Resistant Prostate Cancer Treatment Market Forecast by Application (2018-2023)
11.3 Hospital Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
12 Global Castration Resistant Prostate Cancer Treatment Market Size Forecast (2018-2023)
12.1 Global Castration Resistant Prostate Cancer Treatment Market Size Forecast (2018-2023)
12.2 Global Castration Resistant Prostate Cancer Treatment Market Forecast by Regions (2018-2023)
12.3 North America Castration Resistant Prostate Cancer Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Castration Resistant Prostate Cancer Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Castration Resistant Prostate Cancer Treatment Revenue Market Forecast (2018-2023)
12.6 South America Castration Resistant Prostate Cancer Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Castration Resistant Prostate Cancer Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Castration Resistant Prostate Cancer Treatment Picture
Table Product Specifications of Castration Resistant Prostate Cancer Treatment
Table Global Castration Resista
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
